ADDITIONAL READING

Recommended Reading

Alzheimer’s Association. Alzheimer’s Association Report: 2015 Alzheimer’s disease facts and figures. Alzheimer’s Dement. 2015;11:332-384. Full report available at: https://www.alz.org/facts/downloads/facts_figures_2015.pdf.

Alzheimer’s Association. Early-Onset Dementia: A National Challenge, a Future Crisis. Washington, D.C.: Alzheimer’s Association, 2006.

Beach TG, Monsell SE, Phillips LE, Kukull W. Accuracy of the clinical diagnosis of Alzheimer disease at National Institute on Aging Alzheimer Disease Centers, 2005-2010. J Neuropathol Exp Neurol. 2012;71:266-273.

Bradford A, Kunik ME, Schulz P, Williams SP, Singh H. Missed and delayed diagnosis of dementia in primary care: prevalence and contributing factors. Alzheimer Dis Assoc Disord. 2009;23:306-314.

California Workgroup on Guidelines for Alzheimer’s Disease Management. Guidelines for Alzheimer’s Disease Management. Sacramento, CA. Full report available at: https://www.cdph.ca.gov/programs/alzheimers/Documents/professional_GuidelineFullReport.pdf.

Cordell CB, Borson S, Boustani M, et al. Alzheimer’s Association recommendations for operationalizing the detection of cognitive impairment during the Medicare Annual Wellness Visit in a primary care setting. Alzheimers Dement. 2013;9:141-150.

Cummings JL, Isaacson RS, Schmitt FA, Velting DM. A practical algorithm for managing Alzheimer’s disease: what, when, and why? Ann Clin Transl Neurol. 2015;2:307-323.

Hyman BT, Phelps CH, Beach TG, et al. National Institute on Aging—Alzheimer’s Association guidelines for the neuropathic assessment of Alzheimer’s disease. Alzheimers Dement. 2012;8:1-13.

Johnson KA, Minoshima S, Bohnen NI, et al. Appropriate use criteria for amyloid PET: A report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer’s Association. Alzheimer’s Dement. 2013;9:e1-e16.

Reitz C, Jun G, Naj A, et al. Variants in the ATP-binding cassette transporter (ABCA7), apolipoprotein E 4, and the risk of late-onset Alzheimer disease in African Americans. JAMA. 2013;309(14):1483–92.

Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, et al. Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging–Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 2011;7(3):280–92.

Sutphen CL, Jasielec MS, Shah AR, et al. Longitudinal cerebrospinal fluid biomarker Changes in Preclinical Alzheimer Disease During Middle Age. JAMA Neurol. 2015;72:1029-1042.

Winslow BT, Onysko MK, Stob CM, Hazlewood KA. Treatment of Alzheimer disease. Am Fam Physician. 2011;83:1403-1412.

Epidemiology

Challenges

Diagnosis

Biomarkers

Treatments

Additional Reading